The IPCI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the IPCI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The IPCI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View IPCI Detailed Price Forecast - CNN Money||View IPCI Detailed Summary - Google Finance|
|View IPCI Detailed Summary - Yahoo! Finance||View IPCI Stock Research & Analysis - Zacks.com|
|View IPCI Trends & Analysis - Trade-Ideas||View IPCI Major Holders - Barrons|
|View IPCI Call Transcripts - NASDAQ||View IPCI Breaking News & Analysis - Seeking Alpha|
|View IPCI Annual Report - CompanySpotlight.com||View IPCI OTC Short Report - OTCShortReport.com|
|View IPCI Fundamentals - TradeKing||View IPCI SEC Filings - Bar Chart|
|View Historical Prices for IPCI - The WSJ||View Performance/Total Return for IPCI - Morningstar|
|View the Analyst Estimates for IPCI - MarketWatch||View the Earnings History for IPCI - CNBC|
|View the IPCI Earnings - StockMarketWatch||View IPCI Buy or Sell Recommendations - MacroAxis|
|View the IPCI Bullish Patterns - American Bulls||View IPCI Short Pain Metrics - ShortPainBot.com|
|View IPCI Stock Mentions - StockTwits||View IPCI Stock Mentions - PennyStockTweets|
|View IPCI Stock Mentions - Twitter||View IPCI Investment Forum News - Investor Hub|
|View IPCI Stock Mentions - Yahoo! Message Board||View IPCI Stock Mentions - Seeking Alpha|
|View Insider Transactions for IPCI - SECform4.com||View Insider Transactions for IPCI - Insider Cow|
|View IPCI Major Holdings Summary - CNBC||View Insider Disclosure for IPCI - OTC Markets|
|View Insider Transactions for IPCI - Yahoo! Finance||View Institutional Holdings for IPCI - NASDAQ|
|View IPCI Stock Insight & Charts - FinViz.com||View IPCI Investment Charts - StockCharts.com|
|View IPCI Stock Overview & Charts - BarChart||View IPCI User Generated Charts - Trading View|
Intellipharmaceutics: Fiscal 2Q Earnings Snapshot
Posted on Tuesday July 17, 2018
On a per-share basis, the Toronto-based company said it had a loss of 7 cents. The extended-release drug developer posted revenue of $577,000 in the period. The company's shares closed at 47 cents. A year ...
Intellipharmaceutics Announces Second Quarter 2018 Results
Posted on Monday July 16, 2018
TORONTO, ON / ACCESSWIRE / July 16, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing ...
Intellipharmaceutics Receives Anticipated Additional Staff Determination Letter from NASDAQ
Posted on Friday June 08, 2018
TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received a letter from Nasdaq Listings Qualification staff (the "Staff") formally notifying the Company that its 180-day grace period for the $1.00 per share bid price requirement period has expiredand that therefore the Company is non-compliant with Nasdaq Listing Rule 5550(a)(2). While the Company understands has the opportunity to provide a submission to the Nasdaq Hearings Panel (the''Panel''), it does not intend to do so since the Company proactively addressed the bid price issue at the hearing held on May 17, 2018, and since Panel has already granted the Company a further extension within which to address the bid price issue.
Nasdaq Hearings Panel Grants Intellipharmaceutics' Request for Continued Listing
Posted on Tuesday May 22, 2018
TORONTO, ON / ACCESSWIRE / May 22, 2018 / Intellipharmaceutics International Inc. (NASDAQ: IPCI and TSX: IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has received notice from the Nasdaq Hearings Panel granting its request for continued listing until September 28, 2018 while the Company works to regain compliance with Nasdaq's requirements. At a hearing held on May 17, 2018, the Company presented its plan to regain and maintain compliance with Nasdaq's continued listing requirements.